Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens

SOFT 2023

Society of Forensic toxicologists

Denver, CO, Oct 29-Nov 3, 2023

Oral presentation: Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens

Authors: Neifeld JR, Solano RI, Smith MP, Bartock SH

Specialty: Prescription Drug Monitorig, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Conference Presentation
What’s Next on the Drug Abuse Landscape: Development of Laboratory Testing for Novel Psychoactive Substances (NPS)
Audio Podcast
Patients with Substance Use Disorders in Medication-assisted Treatment (MAT)
Audio Podcast
Presumptive vs Definitive Drug Testing: What You Need to Know
Audio Podcast
Phosphatidylethanol (PEth) blood test - Now available from Quest Diagnostics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.